Key facts
- It has raised $204.9M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Development Bank of Japan, Innovation Network Corporation of Japan, Takenaka, YMC, Asahi Kasei Corporate Venture Capital — 26 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 26 names
- ·Watchlist + deal alerts for PeptiStar
- ·The full record, as it builds
Funding rounds
No funding rounds for PeptiStar are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PeptiStar
Developer of medium-sized molecule pharmaceutical components intended to support drug research, development, and commercial production. The company provides CMC development, process and analytical method development, GMP-compliant manufacturing, and production scale-up for complex compounds such as peptides, oligonucleotide-based substances, and conjugated drug compounds across discovery, clinical development, and commercial stages, enabling pharmaceutical companies to advance drug candidates and maintain stable and compliant manufacturing supply.
- Sector
- Healthcare
- HQ
- Settsu, Japan
- Founded
- 2017
- Employees
- 100
- Website
- peptistarinc.com/
- Ownership
- Privately Held (backing)
PeptiStar doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PeptiStar shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PeptiStar in its N-PORT filings yet. We sweep new filings monthly.